Company News 

Consort bounces on drug approval

Consort bounces on drug approval

Consort Medical's (CSRT) shares bounced back on news that US regulator, the Food and Drug Administration (FDA), has approved Wixela Hub – a generic copy of GlaxoSmithKline’s (GSK) respiratory drug Advair – made by US-listed pharma group Mylan (US:MYL).

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now